Live feed16:05:00·708dPRReleasevia QuantisnowUltragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome ProgramByQuantisnow·Wall Street's wire, on your screen.RARE· Ultragenyx Pharmaceutical Inc.Health Care
